Furthermore, these retrospective data often report events from the “early days” of CAR-T therapy, where consequently tocilizumab, an IL-6 inhibitor which significantly reduces the clinical impact of CRS, was not used. The gene discussed is IL6; the disease is congenital rubella syndrome.